Bluejay announces Symphony IL-6 Test abstract accepted for SAEM 2026 meeting

Bluejay Diagnostics, Inc.

Abstract accepted for presentation at Society of Academic Emergency Medicine Annual Meeting, May 18-21, 2026 in Atlanta.
Presentation reports SYMON-I pilot study data: IL-6 levels in ED linked to organ dysfunction (SOFA scores) in sepsis patients.
Principal investigator Nathan Shapiro: IL-6 measured in ED may be associated with subsequent organ dysfunction.
Ongoing SYMON-II pivotal study to validate IL-6 as prognostic biomarker for mortality, to support FDA 510(k) submission.
Company developing rapid near-patient Symphony IL-6 Test for sepsis triage and monitoring.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.